These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 9120290)
1. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290 [TBL] [Abstract][Full Text] [Related]
2. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028 [TBL] [Abstract][Full Text] [Related]
3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide. Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491 [TBL] [Abstract][Full Text] [Related]
4. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978 [TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075 [TBL] [Abstract][Full Text] [Related]
9. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma. Ding W; Fong C Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173 [TBL] [Abstract][Full Text] [Related]
10. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972 [TBL] [Abstract][Full Text] [Related]
11. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen. Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466 [TBL] [Abstract][Full Text] [Related]
12. Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells. Murray RJ; Brooks JM; Rickinson AB; Rowe M Eur J Immunol; 1990 Mar; 20(3):659-64. PubMed ID: 1690661 [TBL] [Abstract][Full Text] [Related]
13. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425 [TBL] [Abstract][Full Text] [Related]
15. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells]. Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075 [TBL] [Abstract][Full Text] [Related]
16. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009 [TBL] [Abstract][Full Text] [Related]
17. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Khanna R; Burrows SR; Nicholls J; Poulsen LM Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052 [TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Lee SP; Morgan S; Skinner J; Thomas WA; Jones SR; Sutton J; Khanna R; Whittle HC; Rickinson AB Eur J Immunol; 1995 Jan; 25(1):102-10. PubMed ID: 7531142 [TBL] [Abstract][Full Text] [Related]
19. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493 [TBL] [Abstract][Full Text] [Related]
20. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. Solache A; Morgan CL; Dodi AI; Morte C; Scott I; Baboonian C; Zal B; Goldman J; Grundy JE; Madrigal JA J Immunol; 1999 Nov; 163(10):5512-8. PubMed ID: 10553078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]